Susquehanna International Group’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Susquehanna International Group’s Portfolio NVLN Stock Details NVLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-56,900	Closed	-$49K	–	10403
2018 Q4	$49K	Sell	56,900 -100	-0.2%	-$113	﹤0.01%	8494
2018 Q3	$169K	Buy	+57,000	New	+$202K	﹤0.01%	8343
2018 Q2	–	Sell	-12,700	Closed	-$44K	–	10837
2018 Q1	$44K	Sell	12,700 -20,200	-61%	-$85.6K	﹤0.01%	8991
2017 Q4	$103K	Buy	+32,900	New	+$158K	﹤0.01%	8678
2017 Q1	–	Sell	-28,400	Closed	-$239K	–	10516
2016 Q4	$239K	Buy	+28,400	New	+$252K	﹤0.01%	8383

Other funds holding NVLN

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

HVC

Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

FSA

Franklin Street Advisors Chapel Hill, North Carolina $1.79B AUM 28.1% 1-Year Est. Return

Susquehanna International Group's NVLN Position: Q3 2019 in Review

Susquehanna International Group sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q3 2019, closing a stake of 12,454 shares — an estimated $10K sold.

Susquehanna International Group first reported a position in NVLN in Q4 2017 and held it in 3 quarters. The position peaked at $42K in Q4 2018. 31 funds tracked by Wall St. Rank hold NVLN as of Q3 2019.

Susquehanna International Group reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q3 2019 after selling out during the quarter.
Susquehanna International Group sold 12,454 Novelion Therapeutics Inc. Common Shares shares in Q3 2019, an estimated $10K.
Susquehanna International Group first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2017 and held it in 3 quarters.
Susquehanna International Group's Novelion Therapeutics Inc. Common Shares position peaked at $42K in Q4 2018.
31 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q3 2019.

Based on Susquehanna International Group's 13F filing for Q3 2019, filed 14 Nov 2019.